Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial-Reference-Cited by-同舟云学术

Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

Published:2024-08 Issue:2 Volume:86 Page:90-94
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Fitzgerald Kelly N.^ORCID,Lee Chung-Han,Voss Martin H.,Carlo Maria I.,Knezevic Andrea,Peralta Laura,Chen Yingbei,Lefkowitz Robert A.,Shah Neil J.,Owens Colette N.,McHugh Deaglan J.,Aggen David H.,Laccetti Andrew L.,Kotecha Ritesh R.,Feldman Darren R.,Motzer Robert J.^ORCID

Publisher

Elsevier BV

Reference15 articles.

1. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma;Fernández-Pello;Eur Urol,2017

2. Tumor and microenvironment evolution during immunotherapy with nivolumab;Riaz;Cell,2017

3. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma;McDermott;J Clin Oncol,2021

4. Safety and efficacy of nivolumab in patients with advanced non–clear cell renal cell carcinoma: results from the phase IIIb/IV CheckMate 374 study;Vogelzang;Clin Genitourin Cancer,2020

5. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial;Pal;Lancet,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions;Current Oncology Reports;2024-06-07